Embattled Biogen sells stake in biosimilars venture for $2.3B

Embattled Biogen sells stake in biosimilars venture for $2.3B
·2 min read

Embattled Cambridge biotech Biogen Inc. will make some quick cash by selling its stake in a biosimilars venture it started more than 10 years ago with Samsung Bioepsis, a subsidiary of the Korean biopharmaceutical company Samsung Biologics.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting